Antidepressant made with party drug gets FDA panel’s backing

Feb 13, 2019

An experimental nasal spray developed by Johnson & Johnson to treat depression could be headed for FDA approval. 

The treatment, esketamine, includes a compound similar to ketamine, an often-abused drug that can induce sedation and a trance-like state. But J&J’s treatment is believed to restore nerve cell connections that improve depression symptoms. One panel member who voted to recommend approval for esketamine said the drug could be a “game-changer” for depression patients. 

An FDA advisory panel voted 14-2 in favor of approving esketamine for patients who have already tried two other depression treatments. The panel also recommended that the FDA implement a risk evaluation and mitigation strategy for how esketamine is prescribed and dispensed.  

The FDA is expected to make a final approval decision about esketamine by March 4. 

Read the full Reuters report.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments